RPCEC00000172已完成1 期
Randomized double blind controlled, phase I clinical trial, to assess safety, reactogenicity and immunogenicity of the 638 vaccine candidate, in healthy female and male children and adolescents aged from 5 to 17 years old from Cienfuegos Province, Cuba.
Center for Research and Production of Sera and Vaccines (Finlay Institute)0 个研究点目标入组 60 人开始时间: 2013年10月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Prevention
入排标准
- 年龄范围
- 5 years 至 17 years（—）
- 性别
- All
入选标准
- •1.Female and male adolescents and children aged from 5 to 17 years old, located between the 10th and 90th percentile, according to the Cuban population nutritional evaluation tables.
- •2.Good physical and mental health criteria established by anamnesia, physical examination, and results of the hematology, hemochemistry and urine laboratory tests within reference parameters, before the beginning of the study.
- •3.Expressed willfulness by means of a written Informed Consent, signed either by the father, the mother or the legal tutor of the girls and boys, and by the approval of the children of 10 or more years old..
排除标准
- •The participant should not be included if complies with at least one of the following criteria:
- •1.Transmissible or non-transmissible chronic disease referenced or detected during a clinical examination.
- •2.Acute illness detected in the previous week when the investigational product be fed, with or without fever.
- •3.Anemia with hemoglobin levels below 10 g / dl, according to the WHO criteria.
- •4.Axiliary temperature = 37.5°C immediately previous to the Investigational products be fed.
- •5.Congenital or acquired immunodeficiency.
- •6.To be under immunosuppressive therapy (more than 14 days before administration of the Investigational Products) or other medication that modifies the immune status, excluding topical or inhaled steroids.
- •7.History of therapy with immunoglobulin or blood products within 6 months prior to the administration of the vaccine candidate or placebo.
- •8.History of antibiotic therapy during the 28 days prior to the administration of the Investigational Products or benzathine penicillin therapy.
- •9.Allergy to medications under study.
- •10.Change in the normal stool pattern of the volunteers in the month previous to the study.
- •11.History of acute diarrhea event 30 days before the clinical trial starts or history of chronic diarrhea events.
- •12.At least one episode of abdominal pain for more than 2 weeks in the last 30 days and (or) anorexia, nausea, malaise or vomiting in the last 24 hours.
- •13.Antecedent of cholera disease in the last three years.
- •14.Previous history of immunization with vaccines against cholera.
- •15.V. cholerae O1 Positive stool culture.
- •16.Volunteers with vibriocidal antibody titer more than 20, seven days before the investigational products feeding.
- •17.Volunteers with IgG antibody titers by ELISA cholera antitoxin, seven days previous to the investigational products feeding.
- •18.History of allergic reactions to any component of the vaccine candidate, placebo or antacid as well as milk intolerance.
- •19.Positive pregnancy test in menstruant girls .
研究者
相似试验
进行中（未招募）
不适用
Phase I/II study to investigate the safety and immunogenicity of a Lyme Borreliosis vaccine (mv rOspA LB Vaccine) in healthy subjects aged 18 to 70 years.EUCTR2010-023384-18-DEBaxter Innovations GmbH650
进行中（未招募）
不适用
Phase I/II study to investigate the safety and immunogenicity of a Lyme Borreliosis vaccine (mv rOspA LB Vaccine) in healthy subjects aged 18 to 70 years.-) To obtain safety and immunogenicity data of different dose levels of a mv rOspA LB Vaccine with and without adjuvant in seronegative healthy volunteers aged 18 to 70 years. The outcome shall provide the basis for dose/formulation selection for Section 2 of the study.-) To evaluate the safety and immunogenicity of the optimal dose(s)/formulation of the mv rOspA LB vaccine in a larger population of seronegative and seropositive healthy subjects aged 18 to 70 years.MedDRA version: 16.0Level: LLTClassification code 10067559Term: Lyme borreliosisSystem Organ Class: 100000004862EUCTR2010-023384-18-ATBaxter Innovations GmbH650
招募中
1 期
A study to determine the safety, tolerability and ability to provoke an immune response of graded doses of the STX-100/Alhydrogel vaccine in healthy volunteersACTRN12617001027303Clinical Network Services (CNS) Pty Ltd20
进行中（未招募）
不适用
Safety and immunogenicity study of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccine 2830930A when given as 1 dose to healthy toddlers aged 12-23 months.EUCTR2011-002225-22-DEGlaxoSmithKline Biologicals
进行中（未招募）
1 期
Treatment of COVID-19 with allogeneic mesenchymal cells (MSV®).COVID-19MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001682-36-ESCITOSPIN S.L.24